Staffan Strömberg, Ph.D.

CEO since 2013. Born 1967.

Staffan has over 20 years of experience in the pharmaceutical industry. Besides his role as Head of Medical Devices at the Swedish Medical Products Agency, he has also been Vice President of Nicox France, and had management positions at AstraZeneca. Staffan has particular experience in the development of orphan drugs as he was Head of R&D of Swedish Orphan Biovitrum AB (Sobi).

Shareholding in the Company: 43,228 shares of series B and 50,000 warrants 2020/2024 and 120,000 warrants 2022/2025 and 45,864 shares of series B through the wholly-owned company Eteboxagu AB.

Maria Ekdahl

Chief Financial Officer since 2022. Born 1973

Maria, has a degree in economics from Linné University, has a solid financial background in both accounting and business controlling. She has experience from various organizations such as Telenor, Karolinska, Coca-Cola and the Swedish Film Institute.

Anders Kronström, M.Sc., M.B.A.

Chief Operating Officer Since 2018. Born 1967.

Anders Kronström has over 20 years of experience working in the pharmaceutical industry. His experience spans across all stages of drug development in different disease segments. During his career at AstraZeneca he has had senior leadership positions within Project Management and Business Development. More recently, he was a CEO of Biosergen AS, a Norwegian biotechnology company.

Shareholding in the Company: 8 170 shares of series B and 40,000 warrants 2020/2024 and 75,000 warrants 2022/2025.

Professor Jonas Rastad, MD, Ph.D.

CHIEF MEDICAL OFFICER

Jonas has 20 years of experience in academic surgery and has published 250 papers in peer review journals. He has served in several managerial roles in AstraZeneca in Sweden, Japan, the UK and the US. He also has 13 years experience in senior public leadership roles including Head of County Hospital of Kalmar, Head of Västerbotten County Council and CEO of Region Skåne.

Robert Molander, MBA

Chief Commercial Officer since 2022. Born 1965.

Robert Molander resigned from the IBT Board May 2022, and at the same time, assumed the operational role as Chief Commercial Officer within the management team for the company. He holds an MBA from Washington University as well as two bachelor's degrees from Miami University in Economics and International Studies. Robert Molander has 25 years of experience working in life science organizations with launching and commercializing pharmaceuticals in the United States at organizations such as Pfizer and Novartis. He has also served as an Executive Council Member at the Harvard Medical School.


Shareholding in the Company: 10 000 series B Shares and 20,000 warrants 2022/2025.




Holdings in Infant Bacterial Therapeutics AB as of May 7, 2021.